July 17, 2012 the FDA approved a new drug Qsymia for obesity treatment. The new drug Qsymia for obesity treatment consists of two pharmacological substances Phentermine and Topiramate.
Feasibility of combined use of Phentermine and Topiramate is proven by the fact that Topiramate has anorexigenic effect just as Phentermine. Therefore Topiramate increases pharmacological action of Phentermine, allowing to reduce the dose of Phentermine twice.
It should be noted though that Topiramate possesses slight anorexigenic effect and even maximal Topiramate doses provide no significant effect. Hence, Topiramate cannot be prescribed for monotherapy of obesity and can be only used in combination with Phentermine.
Celexa is a trade name of Citalopram antidepressant that is a selective serotonin reuptake inhibitor (SSRI). Celexa (Citalopram) drug for the treatment of depressive disorders is produced by Forest Laboratories.
Phentermine anorexigenic drug stimulates the release of norepinephrine and dopamine by the nerve endings in hypothalamus saturation center. While working on those brain parts that are responsible for appetite, Phentermine relieves hunger sensation. Therefore when using Phentermine, the amount of consumed food reduces and so the body starts to lose weight.
Sibutramine drug for weight loss has pharmacological property to inhibit serotonin-norepinephrine reuptake from the synaptic cleft of the hypothalamus. Sibutramine enhances the interaction between norepinephrine and serotonergic systems, thereby suppressing the appetite and increasing thermogenesis.